{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:15:55Z","timestamp":1784855755020,"version":"3.55.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000185","name":"DARPA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.virol.2021.02.003","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T08:15:23Z","timestamp":1614327323000},"page":"70-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["On the road to ending the COVID-19 pandemic: Are we there yet?"],"prefix":"10.1016","volume":"557","author":[{"given":"James Brett","family":"Case","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-8152","authenticated-orcid":false,"given":"John M.","family":"Errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-3165","authenticated-orcid":false,"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2021.02.003_bib1","article-title":"A neutralizing monoclonal antibody for hospitalized patients with COVID-19","author":"ACTIV-3\/TICO LY-CoV555 Study Group","year":"2020","journal-title":"N Engl J Med NEJMoa2033130"},{"key":"10.1016\/j.virol.2021.02.003_bib2","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.virol.2021.02.003_bib3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.2000583","article-title":"A potently neutralizing antibody protects mice against SARS-CoV-2 infection","volume":"205","author":"Alsoussi","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2021.02.003_bib4","series-title":"Vaccination Strategies against Highly Variable Pathogens, Current Topics in Microbiology and Immunology","first-page":"1","article-title":"Successful vaccines","author":"Amanna","year":"2018"},{"key":"10.1016\/j.virol.2021.02.003_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0092-1157(89)90032-2","article-title":"Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects","volume":"17","author":"Aoki","year":"1989","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.virol.2021.02.003_bib6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct early serological signatures track with SARS-CoV-2 survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2021.02.003_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib9","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.1997.0056","article-title":"Yellow fever vaccines","volume":"25","author":"Barrett","year":"1997","journal-title":"Biologicals"},{"key":"10.1016\/j.virol.2021.02.003_bib11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3121\/cmr.1.2.87","article-title":"Smallpox vaccine: the good, the bad, and the ugly","volume":"1","author":"Belongia","year":"2003","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.virol.2021.02.003_bib14","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.02.003_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","author":"Bournazos","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib16","doi-asserted-by":"crossref","first-page":"20054","DOI":"10.1073\/pnas.1911842116","article-title":"Differential requirements for Fc\u03b3R engagement by protective antibodies against Ebola virus","volume":"116","author":"Bournazos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2021.02.003_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2021.02.003_bib21","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2021.02.003_bib22","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19","author":"Chen","year":"2020","journal-title":"N Engl J Med NEJMoa2029849"},{"key":"10.1016\/j.virol.2021.02.003_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib24","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2021.02.003_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib26","article-title":"\u201cAbsolutely remarkable\u201d: No one who got Moderna's vaccine in trial developed severe COVID-19","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib27","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1126\/science.1155761","article-title":"Virus attenuation by genome-scale changes in codon pair bias","volume":"320","author":"Coleman","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib29","doi-asserted-by":"crossref","first-page":"m1165","DOI":"10.1136\/bmj.m1165","article-title":"Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village","volume":"368","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.virol.2021.02.003_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chom.2020.04.021","article-title":"The challenges of vaccine development against a new virus during a pandemic","volume":"27","author":"Diamond","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2021.02.003_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2021.02.003_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk\u2013specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","article-title":"A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures","volume":"586","author":"Dinnon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib34","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2021.02.003_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.virol.2015.03.017","article-title":"Ferret models of viral pathogenesis","volume":"479\u2013480","author":"Enkirch","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.02.003_bib36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","article-title":"Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2\u2013MPER region","volume":"3","author":"Flyak","year":"2018","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.virol.2021.02.003_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2021.02.003_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav5062","article-title":"Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-Fc\u03b3R interaction on monocytes","volume":"4","author":"Fox","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.virol.2021.02.003_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib40","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrmicro3143","article-title":"A decade after SARS: strategies for controlling emerging coronaviruses","volume":"11","author":"Graham","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2021.02.003_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2021.02.003_bib43","series-title":"Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies","author":"Greaney","year":"2021"},{"key":"10.1016\/j.virol.2021.02.003_bib44","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41590-020-0773-7","article-title":"ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection","volume":"21","author":"Hachim","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2021.02.003_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI80561","article-title":"Towards HIV-1 remission: potential roles for broadly neutralizing antibodies","volume":"126","author":"Halper-Stromberg","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2021.02.003_bib46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib47","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies","volume":"182","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","article-title":"Neutralization of SARS-CoV-2 by destruction of the prefusion spike","volume":"28","author":"Huo","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2021.02.003_bib51","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"JVI","key":"10.1016\/j.virol.2021.02.003_bib52","article-title":"Syrian hamster as an animal model for the study of human influenza virus infection","volume":"92","author":"Iwatsuki-Horimoto","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.02.003_bib53","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","article-title":"Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2","volume":"182","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib55","article-title":"Furin cleavage site is key to SARS-CoV-2 pathogenesis","volume":"581","author":"Johnson","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2021.02.003_bib56","article-title":"LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection","author":"Jones","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2021.02.003_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib59","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib60","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","article-title":"Infection and rapid transmission of SARS-CoV-2 in ferrets","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2021.02.003_bib61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diagmicrobio.2017.07.006","article-title":"Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity","volume":"89","author":"Ko","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.virol.2021.02.003_bib63","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib64","series-title":"A Novel Neutralizing Antibody Targeting Receptor-Binding Domain of SARS-CoV-2","author":"Lee","year":"2020"},{"key":"10.1016\/j.virol.2021.02.003_bib65","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.virol.2021.02.003_bib66","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26738","article-title":"A potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.virol.2021.02.003_bib67","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.virol.2021.02.003_bib68","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1126\/science.abb3221","article-title":"Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)","volume":"368","author":"Li","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib69","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe covid-19 in older adults","author":"Libster","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib70","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.immuni.2020.10.023","article-title":"Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity","volume":"53","author":"Liu","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2021.02.003_bib71","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib72","doi-asserted-by":"crossref","first-page":"45552","DOI":"10.1038\/srep45552","article-title":"Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2021.02.003_bib73","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib74","article-title":"Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","author":"Liu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2021.02.003_bib75","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2021.02.003_bib76","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2021.02.003_bib78","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.virol.2021.02.003_bib79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib80","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3389\/fimmu.2019.02329","article-title":"Syrian hamster as an animal model for the study on infectious diseases","volume":"10","author":"Miao","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2021.02.003_bib81","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/clinids\/19.3.500","article-title":"Antibody-dependent enhancement of infection and the pathogenesis of viral disease","volume":"19","author":"Morens","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2021.02.003_bib82","first-page":"1","article-title":"Prospects for mucosal vaccine: shutting the door on SARS-CoV-2","volume":"59","author":"Mudgal","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2021.02.003_bib83","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2","volume":"585","author":"Munster","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib84","first-page":"669","article-title":"Animal models for COVID-19","volume":"20","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib85","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(95)00211-I","article-title":"Inactivated poliovirus vaccine: past and present experience","volume":"14","author":"Murdin","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2021.02.003_bib86","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.virol.2021.02.003_bib87","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1038\/s41467-020-18159-4","article-title":"A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes","volume":"11","author":"Noy-Porat","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2021.02.003_bib88","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.abe5901","article-title":"Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans","volume":"371","author":"Oude Munnink","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib89","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2021.02.003_bib90","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1473-3099(20)30484-9","article-title":"Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics","volume":"20","author":"Petersen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2021.02.003_bib91","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib93","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","author":"Polack","year":"2020","journal-title":"N Engl. J. Med. NEJMoa2034577"},{"key":"10.1016\/j.virol.2021.02.003_bib94","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2021.02.003_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4830","article-title":"Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody","author":"Rappazzo","year":"2021","journal-title":"Sci. eabf4830"},{"key":"10.1016\/j.virol.2021.02.003_bib97","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1038\/s41467-020-17367-2","article-title":"SARS-CoV-2 is transmitted via contact and via the air between ferrets","volume":"11","author":"Richard","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2021.02.003_bib98","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib99","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","volume":"368","author":"Rockx","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib100","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib101","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.ajpath.2020.08.001","article-title":"Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality","volume":"190","author":"Salazar","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.virol.2021.02.003_bib102","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.virol.2008.07.026","article-title":"An immunosuppressed Syrian golden hamster model for SARS-CoV infection","volume":"380","author":"Schaecher","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.02.003_bib103","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo","volume":"218","author":"Sch\u00e4fer","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib104","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS\u2013coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib106","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2004.05.006","article-title":"Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients","volume":"31","author":"Shi","year":"2004","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.virol.2021.02.003_bib107","article-title":"A randomized trial of convalescent plasma in covid-19 severe pneumonia","author":"Simonovich","year":"2020","journal-title":"N. Engl. J. Med. NEJMoa2031304"},{"key":"10.1016\/j.virol.2021.02.003_bib108","series-title":"Prospective Mapping of Viral Mutations that Escape Antibodies Used to Treat COVID-19","author":"Starr","year":"2020"},{"key":"10.1016\/j.virol.2021.02.003_bib109","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med. eabd2223"},{"key":"10.1016\/j.virol.2021.02.003_bib110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2021.02.003_bib111","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib112","series-title":"Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein","author":"Suryadevara","year":"2021"},{"key":"10.1016\/j.virol.2021.02.003_bib113","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2021.02.003_bib114","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1073\/pnas.070525997","article-title":"Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach","volume":"97","author":"Talon","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2021.02.003_bib115","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"The effect OF prolonged cultivation IN vitro UPON the pathogenicity OF yellow fever virus","volume":"65","author":"Theiler","year":"1937","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib116","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib117","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/JVI.01702-06","article-title":"Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor","volume":"81","author":"Tseng","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.02.003_bib118","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib119","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring","volume":"27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2021.02.003_bib120","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.1128\/JVI.05859-11","article-title":"Poorly Neutralizing Cross-Reactive Antibodies against the Fusion Loop of West Nile Virus Envelope Protein Protect <em>In Vivo<\/em> via Fc\u03b3 Receptor and Complement-Dependent Effector Mechanisms","volume":"85","author":"Vogt","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.02.003_bib121","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","author":"Voysey","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2021.02.003_bib122","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib123","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med. NEJMoa2027906"},{"key":"10.1016\/j.virol.2021.02.003_bib124","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.02.003_bib125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.02.003_bib127","series-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","author":"Wang","year":"2021"},{"key":"10.1016\/j.virol.2021.02.003_bib126","series-title":"Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization","author":"Wang","year":"2021"},{"key":"10.1016\/j.virol.2021.02.003_bib128","series-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","author":"Wang","year":"2021"},{"key":"10.1016\/j.virol.2021.02.003_bib129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib130","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s42255-020-00324-0","article-title":"HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry","volume":"2","author":"Wei","year":"2020","journal-title":"Nat. Metabol."},{"key":"10.1016\/j.virol.2021.02.003_bib131","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.virol.2021.02.003_bib132","author":"WHO"},{"key":"10.1016\/j.virol.2021.02.003_bib133","series-title":"DRAFT Landscape of COVID-19","author":"WHO","year":"2020"},{"key":"10.1016\/j.virol.2021.02.003_bib134","author":"WHO"},{"key":"10.1016\/j.virol.2021.02.003_bib135","series-title":"SARS-CoV-2 501Y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma","author":"Wibmer","year":"2021"},{"key":"10.1016\/j.virol.2021.02.003_bib136","first-page":"1","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"181","author":"Winkler","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2021.02.003_bib137","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib138","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1038\/s41467-020-19146-5","article-title":"Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein","volume":"11","author":"Wrobel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2021.02.003_bib139","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2021.02.003_bib140","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamainternmed.2020.4616","article-title":"Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib141","doi-asserted-by":"crossref","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","article-title":"An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain","volume":"33","author":"Wu","year":"2020","journal-title":"Cell Reports"},{"key":"10.1016\/j.virol.2021.02.003_bib142","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib143","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.virol.2021.02.003_bib144","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","author":"Xia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2021.02.003_bib145","series-title":"Neutralization of SARS-CoV-2 Spike 69\/70 Deletion, E484K, and N501Y Variants by BNT162b2 Vaccine-Elicited Sera","author":"Xie","year":"2021"},{"key":"10.1016\/j.virol.2021.02.003_bib146","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2021.02.003_bib147","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib148","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.02.003_bib149","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","author":"Zhang","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2021.02.003_bib150","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1073\/pnas.1323279111","article-title":"Rapid generation of a mouse model for Middle East respiratory syndrome","volume":"111","author":"Zhao","year":"2014","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.virol.2021.02.003_bib151","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chom.2020.08.004","article-title":"Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor","volume":"28","author":"Zhao","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2021.02.003_bib152","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.02.003_bib153","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2021.02.003_bib154","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2021.02.003_bib155","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2021.02.003_bib156","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682221000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682221000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:54:56Z","timestamp":1758588896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682221000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":153,"alternative-id":["S0042682221000374"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2021.02.003","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the road to ending the COVID-19 pandemic: Are we there yet?","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2021.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}